Venture Partner at Samsara BioCapital · Joined 2026
View Live Interactive Profile →Thomas F. Bumol, Ph.D. joined Samsara BioCapital in January 2026 as a Venture Partner, with over forty years of biopharmaceutical research and development experience across multiple therapeutic areas per the firm's team page. He was Senior Vice President of Biotechnology Discovery Research and the Immunology Therapeutic Area at Eli Lilly, and also President and Site Head of the Lilly Biotechnology Center in San Diego, before retiring in 2017 after a thirty-five-year career. At Lilly his teams discovered and engineered biologic drug candidates across multiple therapeutic areas and established Immunology as a core therapeutic area at the company. The firm states these efforts resulted in over ninety clinical candidates and ten launched therapies, including dulaglutide (Trulicity) in diabetes. No education detail is published on the firm's team page.